Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry

Allan Iversen; Sune Ammentorp Haahr-Pedersen; Christian Joens; Rasmus Mogelvang; Soren Galatius; Anders Galloe; Ulrik Abildgaard; Peter R Hansen; Jan K Madsen; Jan S Jensen

Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry

Allan Iversen, Sune Ammentorp Haahr-Pedersen, Christian Joens, Rasmus Mogelvang, Soren Galatius, Anders Galloe, Ulrik Abildgaard, Peter R Hansen, Jan K Madsen, Jan S Jensen

4 Citationer (Scopus)

Abstract

The prevalence of diabetes mellitus (DM) and ischemic heart disease is increasing. Moreover, patients with DM experiencing an acute coronary syndrome (ACS) have an increased risk of adverse outcomes after revascularization compared to non-diabetics. Data have suggested that the glycoprotein IIb/IIIa inhibitor abciximab might be more efficient in diabetics than in those without DM.

Originalsprog	Engelsk
Tidsskrift	The Journal of invasive cardiology
Vol/bind	23
Udgave nummer	1
Sider (fra-til)	21-6
Antal sider	6
Status	Udgivet - 1 jan. 2011

Adgang til dokumentet

http://www.invasivecardiology.com/articles/impact-abciximab-diabetic-patients-acute-coronary-syndrome-who-undergo-percutaneous-coronar

Citationsformater

Iversen, A., Haahr-Pedersen, S. A., Joens, C., Mogelvang, R., Galatius, S., Galloe, A., Abildgaard, U., Hansen, P. R., Madsen, J. K., & Jensen, J. S. (2011). Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry. The Journal of invasive cardiology, 23(1), 21-6. http://www.invasivecardiology.com/articles/impact-abciximab-diabetic-patients-acute-coronary-syndrome-who-undergo-percutaneous-coronar

Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry. / Iversen, Allan; Haahr-Pedersen, Sune Ammentorp; Joens, Christian et al.
I: The Journal of invasive cardiology, Bind 23, Nr. 1, 01.01.2011, s. 21-6.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Iversen, A, Haahr-Pedersen, SA, Joens, C, Mogelvang, R, Galatius, S, Galloe, A, Abildgaard, U, Hansen, PR, Madsen, JK & Jensen, JS 2011, 'Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry', The Journal of invasive cardiology, bind 23, nr. 1, s. 21-6. <http://www.invasivecardiology.com/articles/impact-abciximab-diabetic-patients-acute-coronary-syndrome-who-undergo-percutaneous-coronar>

@article{93cdb14ec2b44e7596029db707e25e8c,

title = "Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry",

abstract = "The prevalence of diabetes mellitus (DM) and ischemic heart disease is increasing. Moreover, patients with DM experiencing an acute coronary syndrome (ACS) have an increased risk of adverse outcomes after revascularization compared to non-diabetics. Data have suggested that the glycoprotein IIb/IIIa inhibitor abciximab might be more efficient in diabetics than in those without DM.",

author = "Allan Iversen and Haahr-Pedersen, {Sune Ammentorp} and Christian Joens and Rasmus Mogelvang and Soren Galatius and Anders Galloe and Ulrik Abildgaard and Hansen, {Peter R} and Madsen, {Jan K} and Jensen, {Jan S}",

year = "2011",

month = jan,

day = "1",

language = "English",

volume = "23",

pages = "21--6",

journal = "The Journal of invasive cardiology",

issn = "1557-2501",

publisher = "H M P Communications, LLC",

number = "1",

}

TY - JOUR

T1 - Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry

AU - Iversen, Allan

AU - Haahr-Pedersen, Sune Ammentorp

AU - Joens, Christian

AU - Mogelvang, Rasmus

AU - Galatius, Soren

AU - Galloe, Anders

AU - Abildgaard, Ulrik

AU - Hansen, Peter R

AU - Madsen, Jan K

AU - Jensen, Jan S

PY - 2011/1/1

Y1 - 2011/1/1

N2 - The prevalence of diabetes mellitus (DM) and ischemic heart disease is increasing. Moreover, patients with DM experiencing an acute coronary syndrome (ACS) have an increased risk of adverse outcomes after revascularization compared to non-diabetics. Data have suggested that the glycoprotein IIb/IIIa inhibitor abciximab might be more efficient in diabetics than in those without DM.

AB - The prevalence of diabetes mellitus (DM) and ischemic heart disease is increasing. Moreover, patients with DM experiencing an acute coronary syndrome (ACS) have an increased risk of adverse outcomes after revascularization compared to non-diabetics. Data have suggested that the glycoprotein IIb/IIIa inhibitor abciximab might be more efficient in diabetics than in those without DM.

M3 - Journal article

C2 - 21183766

SN - 1557-2501

VL - 23

SP - 21

EP - 26

JO - The Journal of invasive cardiology

JF - The Journal of invasive cardiology

IS - 1

ER -

Impact of abciximab in diabetic patients with acute coronary syndrome who undergo percutaneous coronary intervention: results from a high-volume, single-center registry

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater